ID   STK6_HUMAN              Reviewed;         403 AA.
AC   O14965; O60445; O75873; Q9BQD6; Q9UPG5;
DT   27-JAN-2003, integrated into UniProtKB/Swiss-Prot.
DT   27-JAN-2003, sequence version 2.
DT   02-NOV-2010, entry version 126.
DE   RecName: Full=Serine/threonine-protein kinase 6;
DE            EC=2.7.11.1;
DE   AltName: Full=Aurora kinase A;
DE   AltName: Full=Aurora/IPL1-related kinase 1;
DE            Short=ARK-1;
DE            Short=Aurora-related kinase 1;
DE            Short=hARK1;
DE   AltName: Full=Breast tumor-amplified kinase;
DE   AltName: Full=Serine/threonine-protein kinase 15;
DE   AltName: Full=Serine/threonine-protein kinase aurora-A;
GN   Name=AURKA; Synonyms=AIK, ARK1, AURA, BTAK, STK15, STK6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Blood;
RX   MEDLINE=97298083; PubMed=9153231; DOI=10.1074/jbc.272.21.13766;
RA   Kimura M., Kotani S., Hattori T., Sumi N., Yoshioka T., Todokoro K.,
RA   Okano Y.;
RT   "Cell cycle-dependent expression and spindle pole localization of a
RT   novel human protein kinase, Aik, related to Aurora of Drosophila and
RT   yeast Ipl1.";
RL   J. Biol. Chem. 272:13766-13771(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ILE-57.
RX   MEDLINE=98183439; PubMed=9514916; DOI=10.1006/bbrc.1998.8250;
RA   Shindo M., Nakano H., Kuroyanagi H., Shirasawa T., Mihara M.,
RA   Gilbert D.J., Jenkins N.A., Copeland N.G., Yagita H., Okumura K.;
RT   "cDNA cloning, expression, subcellular localization, and chromosomal
RT   assignment of mammalian aurora homologues, aurora-related kinase (ARK)
RT   1 and 2.";
RL   Biochem. Biophys. Res. Commun. 244:285-292(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ILE-31.
RC   TISSUE=Mammary gland;
RX   MEDLINE=98442657; PubMed=9771714; DOI=10.1038/2496;
RA   Zhou H., Kuang J., Zhong L., Kuo W.-L., Gray J.W., Sahin A.,
RA   Brinkley B.R., Sen S.;
RT   "Tumour amplified kinase STK15/BTAK induces centrosome amplification,
RT   aneuploidy and transformation.";
RL   Nat. Genet. 20:189-193(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Wang L., Thibodeau S.N.;
RT   "Mutational analysis of the STK15 gene in human tumors.";
RL   Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   MEDLINE=21638749; PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cervix, Colon, Kidney, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   UBIQUITINATION, PROTEASOMAL DEGRADATION, AND MUTAGENESIS OF ARG-205.
RX   PubMed=10851084; DOI=10.1038/sj.onc.1203609;
RA   Honda K., Mihara H., Kato Y., Yamaguchi A., Tanaka H., Yasuda H.,
RA   Furukawa K., Urano T.;
RT   "Degradation of human Aurora2 protein kinase by the anaphase-promoting
RT   complex-ubiquitin-proteasome pathway.";
RL   Oncogene 19:2812-2819(2000).
RN   [8]
RP   INDUCTION.
RX   MEDLINE=21895866; PubMed=11790771; DOI=10.1074/jbc.M108252200;
RA   Tanaka M., Ueda A., Kanamori H., Ideguchi H., Yang J., Kitajima S.,
RA   Ishigatsubo Y.;
RT   "Cell-cycle-dependent regulation of human aurora A transcription is
RT   mediated by periodic repression of E4TF1.";
RL   J. Biol. Chem. 277:10719-10726(2002).
RN   [9]
RP   INTERACTION WITH TACC1.
RX   PubMed=14603251; DOI=10.1038/sj.onc.1206972;
RA   Conte N., Delaval B., Ginestier C., Ferrand A., Isnardon D.,
RA   Larroque C., Prigent C., Seraphin B., Jacquemier J., Birnbaum D.;
RT   "TACC1-chTOG-Aurora A protein complex in breast cancer.";
RL   Oncogene 22:8102-8116(2003).
RN   [10]
RP   FUNCTION, INTERACTION WITH BRCA1, PHOSPHORYLATION AT THR-288, AND
RP   MUTAGENESIS OF LYS-162.
RX   PubMed=14990569; DOI=10.1074/jbc.M311780200;
RA   Ouchi M., Fujiuchi N., Sasai K., Katayama H., Minamishima Y.A.,
RA   Ongusaha P.P., Deng C., Sen S., Lee S.W., Ouchi T.;
RT   "BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M
RT   transition.";
RL   J. Biol. Chem. 279:19643-19648(2004).
RN   [11]
RP   INTERACTION WITH CPEB1.
RX   PubMed=15966895; DOI=10.1111/j.1365-2443.2005.00870.x;
RA   Sasayama T., Marumoto T., Kunitoku N., Zhang D., Tamaki N.,
RA   Kohmura E., Saya H., Hirota T.;
RT   "Over-expression of Aurora-A targets cytoplasmic polyadenylation
RT   element binding protein and promotes mRNA polyadenylation of Cdk1 and
RT   cyclin B1.";
RL   Genes Cells 10:627-638(2005).
RN   [12]
RP   INTERACTION WITH BORA.
RX   PubMed=16890155; DOI=10.1016/j.devcel.2006.06.002;
RA   Hutterer A., Berdnik D., Wirtz-Peitz F., Zigman M., Schleiffer A.,
RA   Knoblich J.A.;
RT   "Mitotic activation of the kinase Aurora-A requires its binding
RT   partner Bora.";
RL   Dev. Cell 11:147-157(2006).
RN   [13]
RP   FUNCTION.
RX   PubMed=18056443; DOI=10.1158/0008-5472.CAN-07-2578;
RA   Sankaran S., Crone D.E., Palazzo R.E., Parvin J.D.;
RT   "Aurora-A kinase regulates breast cancer associated gene 1 inhibition
RT   of centrosome-dependent microtubule nucleation.";
RL   Cancer Res. 67:11186-11194(2007).
RN   [14]
RP   INTERACTION WITH ARHGEF2.
RX   PubMed=17488622; DOI=10.1016/j.devcel.2007.03.014;
RA   Birkenfeld J., Nalbant P., Bohl B.P., Pertz O., Hahn K.M.,
RA   Bokoch G.M.;
RT   "GEF-H1 modulates localized RhoA activation during cytokinesis under
RT   the control of mitotic kinases.";
RL   Dev. Cell 12:699-712(2007).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-369, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-51, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=19007248; DOI=10.1021/ac801708p;
RA   Wang B., Malik R., Nigg E.A., Korner R.;
RT   "Evaluation of the low-specificity protease elastase for large-scale
RT   phosphoproteome analysis.";
RL   Anal. Chem. 80:9526-9533(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-41; SER-51 AND SER-83,
RP   AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [18]
RP   FUNCTION.
RX   PubMed=18615013; DOI=10.1038/nature07185;
RA   Macurek L., Lindqvist A., Lim D., Lampson M.A., Klompmaker R.,
RA   Freire R., Clouin C., Taylor S.S., Yaffe M.B., Medema R.H.;
RT   "Polo-like kinase-1 is activated by aurora A to promote checkpoint
RT   recovery.";
RL   Nature 455:119-123(2008).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [20]
RP   FUNCTION, AUTOPHOSPHORYLATION, AND INTERACTION WITH PARD3.
RX   PubMed=19812038; DOI=10.1074/jbc.M109.055897;
RA   Khazaei M.R., Puschel A.W.;
RT   "Phosphorylation of the par polarity complex protein Par3 at serine
RT   962 is mediated by aurora A and regulates its function in neuronal
RT   polarity.";
RL   J. Biol. Chem. 284:33571-33579(2009).
RN   [21]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH KIF2A.
RX   PubMed=19351716; DOI=10.1242/jcs.044321;
RA   Jang C.Y., Coppinger J.A., Seki A., Yates J.R. III, Fang G.;
RT   "Plk1 and Aurora A regulate the depolymerase activity and the cellular
RT   localization of Kif2a.";
RL   J. Cell Sci. 122:1334-1341(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-53, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [23]
RP   FUNCTION, INTERACTION WITH TPX2, PHOSPHORYLATION AT THR-287 AND
RP   THR-288, AND MUTAGENESIS OF THR287.
RX   PubMed=19668197; DOI=10.1038/ncb1919;
RA   Mori D., Yamada M., Mimori-Kiyosue Y., Shirai Y., Suzuki A., Ohno S.,
RA   Saya H., Wynshaw-Boris A., Hirotsune S.;
RT   "An essential role of the aPKC-Aurora A-NDEL1 pathway in neurite
RT   elongation by modulation of microtubule dynamics.";
RL   Nat. Cell Biol. 11:1057-1068(2009).
RN   [24]
RP   INTERACTION WITH TPX2, MUTAGENESIS OF GLY-198, SUBCELLULAR LOCATION,
RP   AND FUNCTION.
RX   PubMed=19357306; DOI=10.1073/pnas.0900833106;
RA   Fu J., Bian M., Liu J., Jiang Q., Zhang C.;
RT   "A single amino acid change converts Aurora-A into Aurora-B-like
RT   kinase in terms of partner specificity and cellular function.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:6939-6944(2009).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 107-403 IN COMPLEX WITH
RP   ADENOSINE, AND CATALYTIC ACTIVITY.
RX   PubMed=12237287; DOI=10.1074/jbc.C200426200;
RA   Cheetham G.M., Knegtel R.M., Coll J.T., Renwick S.B., Swenson L.,
RA   Weber P., Lippke J.A., Austen D.A.;
RT   "Crystal structure of aurora-2, an oncogenic serine/threonine
RT   kinase.";
RL   J. Biol. Chem. 277:42419-42422(2002).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 125-391 IN COMPLEX WITH ADP.
RX   MEDLINE=22357219; PubMed=12467573; DOI=10.1016/S0969-2126(02)00907-3;
RA   Nowakowski J., Cronin C.N., McRee D.E., Knuth M.W., Nelson C.G.,
RA   Pavletich N.P., Rogers J., Sang B.C., Scheibe D.N., Swanson R.V.,
RA   Thompson D.A.;
RT   "Structures of the cancer-related Aurora-A, FAK, and EphA2 protein
RT   kinases from nanovolume crystallography.";
RL   Structure 10:1659-1667(2002).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 122-403 IN COMPLEX WITH TPX2,
RP   MUTAGENESIS OF ASP-274, ACTIVE SITE, AND PHOSPHORYLATION AT THR-287
RP   AND THR-288.
RX   PubMed=14580337; DOI=10.1016/S1097-2765(03)00392-7;
RA   Bayliss R., Sardon T., Vernos I., Conti E.;
RT   "Structural basis of Aurora-A activation by TPX2 at the mitotic
RT   spindle.";
RL   Mol. Cell 12:851-862(2003).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 123-401 IN COMPLEXES WITH
RP   ADPNP AND 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR, AND CATALYTIC
RP   ACTIVITY.
RX   PubMed=16337122; DOI=10.1016/j.bmcl.2005.11.053;
RA   Heron N.M., Anderson M., Blowers D.P., Breed J., Eden J.M., Green S.,
RA   Hill G.B., Johnson T., Jung F.H., McMiken H.H., Mortlock A.A.,
RA   Pannifer A.D., Pauptit R.A., Pink J., Roberts N.J., Rowsell S.;
RT   "SAR and inhibitor complex structure determination of a novel class of
RT   potent and specific Aurora kinase inhibitors.";
RL   Bioorg. Med. Chem. Lett. 16:1320-1323(2006).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 100-403 IN COMPLEXES WITH
RP   SYNTHETIC INHIBITORS, AND FUNCTION.
RX   PubMed=17125279; DOI=10.1021/jm060897w;
RA   Fancelli D., Moll J., Varasi M., Bravo R., Artico R., Berta D.,
RA   Bindi S., Cameron A., Candiani I., Cappella P., Carpinelli P.,
RA   Croci W., Forte B., Giorgini M.L., Klapwijk J., Marsiglio A.,
RA   Pesenti E., Rocchetti M., Roletto F., Severino D., Soncini C.,
RA   Storici P., Tonani R., Zugnoni P., Vianello P.;
RT   "1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent
RT   aurora kinase inhibitor with a favorable antitumor kinase inhibition
RT   profile.";
RL   J. Med. Chem. 49:7247-7251(2006).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 125-391 IN COMPLEX WITH
RP   VX-680 AND TPX2, PHOSPHORYLATION AT THR-288, MASS SPECTROMETRY, AND
RP   SUBUNIT.
RX   PubMed=18662907; DOI=10.1110/ps.036590.108;
RA   Zhao B., Smallwood A., Yang J., Koretke K., Nurse K., Calamari A.,
RA   Kirkpatrick R.B., Lai Z.;
RT   "Modulation of kinase-inhibitor interactions by auxiliary protein
RT   binding: crystallography studies on Aurora A interactions with VX-680
RT   and with TPX2.";
RL   Protein Sci. 17:1791-1797(2008).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 127-388 IN COMPLEX WITH ADP,
RP   CHARACTERIZATION OF VARIANTS ARG-155 AND MET-174, AND INTERACTION WITH
RP   TPX2.
RX   PubMed=19801554; DOI=10.1074/jbc.M109.032722;
RA   Bibby R.A., Tang C., Faisal A., Drosopoulos K., Lubbe S., Houlston R.,
RA   Bayliss R., Linardopoulos S.;
RT   "A cancer-associated aurora A mutant is mislocalized and misregulated
RT   due to loss of interaction with TPX2.";
RL   J. Biol. Chem. 284:33177-33184(2009).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 123-401 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=19140666; DOI=10.1021/jm801270e;
RA   Coumar M.S., Leou J.S., Shukla P., Wu J.S., Dixit A.K., Lin W.H.,
RA   Chang C.Y., Lien T.W., Tan U.K., Chen C.H., Hsu J.T., Chao Y.S.,
RA   Wu S.Y., Hsieh H.P.;
RT   "Structure-based drug design of novel Aurora kinase A inhibitors:
RT   structural basis for potency and specificity.";
RL   J. Med. Chem. 52:1050-1062(2009).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 125-391 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=19402633; DOI=10.1021/jm9000314;
RA   Aliagas-Martin I., Burdick D., Corson L., Dotson J., Drummond J.,
RA   Fields C., Huang O.W., Hunsaker T., Kleinheinz T., Krueger E.,
RA   Liang J., Moffat J., Phillips G., Pulk R., Rawson T.E., Ultsch M.,
RA   Walker L., Wiesmann C., Zhang B., Zhu B.Y., Cochran A.G.;
RT   "A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with
RT   unusually high selectivity against Aurora B.";
RL   J. Med. Chem. 52:3300-3307(2009).
RN   [34]
RP   VARIANTS ILE-31 AND ILE-57.
RX   PubMed=15867347; DOI=10.1158/0008-5472.CAN-04-2149;
RA   Kimura M.T., Mori T., Conroy J., Nowak N.J., Satomi S., Tamai K.,
RA   Nagase H.;
RT   "Two functional coding single nucleotide polymorphisms in STK15
RT   (Aurora-A) coordinately increase esophageal cancer risk.";
RL   Cancer Res. 65:3548-3554(2005).
RN   [35]
RP   VARIANTS ILE-31 AND ILE-57.
RX   PubMed=16011022;
RA   Chen L., Ao X., Ren Q., Wang Z.N., Lu C., Xu Y., Jiang L., Luo Y.,
RA   Xu H.M., Zhang X.;
RT   "Linkage disequilibrium and haplotype analysis of two single
RT   nucleotide polymorphisms in STK15 in Chinese.";
RL   Yi Chuan Xue Bao 32:331-336(2005).
RN   [36]
RP   VARIANT ILE-31.
RX   PubMed=16762494; DOI=10.1016/j.canlet.2006.05.002;
RA   Tchatchou S., Wirtenberger M., Hemminki K., Sutter C., Meindl A.,
RA   Wappenschmidt B., Kiechle M., Bugert P., Schmutzler R.K.,
RA   Bartram C.R., Burwinkel B.;
RT   "Aurora kinases A and B and familial breast cancer risk.";
RL   Cancer Lett. 247:266-272(2007).
RN   [37]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-31; LEU-50; ILE-57; ARG-155;
RP   MET-174 AND VAL-373.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Contributes to the regulation of cell cycle progression.
CC       Required for normal mitosis. Associates with the centrosome and
CC       the spindle microtubules during mitosis and functions in
CC       centrosome maturation, spindle assembly, maintenance of spindle
CC       bipolarity, centrosome separation and mitotic checkpoint control.
CC       Phosphorylates numerous target proteins, including ARHGEF2, BRCA1,
CC       KIF2A, NDEL1, PARD3, PLK1 and BORA. Regulates KIF2A tubulin
CC       depolymerase activity (By similarity). Required for normal axon
CC       formation. Plays a role in microtubule remodeling during neurite
CC       extension. Important for microtubule formation and/or
CC       stabilization.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- SUBUNIT: Interacts with TPX2. Interacts with TACC1 and CPEB1.
CC       Interacts with its substrates BORA, BRCA1, KIF2A, PARD3 and
CC       ARHGEF2. Interaction with BORA promotes phosphorylation of PLK1.
CC   -!- INTERACTION:
CC       Q9NWT8:AURKAIP1; NbExp=2; IntAct=EBI-448680, EBI-448665;
CC       P42771:CDKN2A; NbExp=1; IntAct=EBI-448680, EBI-375053;
CC       Q01469:FABP5; NbExp=1; IntAct=EBI-448680, EBI-1054073;
CC       P04198:MYCN; NbExp=2; IntAct=EBI-448680, EBI-878369;
CC       P61026:RAB10; NbExp=1; IntAct=EBI-448680, EBI-726075;
CC       P04179:SOD2; NbExp=1; IntAct=EBI-448680, EBI-716989;
CC       O75410:TACC1; NbExp=1; IntAct=EBI-448680, EBI-624237;
CC       Q9ULW0:TPX2; NbExp=1; IntAct=EBI-448680, EBI-1037322;
CC       P68036:UBE2L3; NbExp=1; IntAct=EBI-448680, EBI-711173;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, centrosome.
CC       Cytoplasm, cytoskeleton, spindle pole. Note=Detected at the
CC       neurite hillock in developing neurons (By similarity). Localizes
CC       on centrosomes in interphase cells and at each spindle pole in
CC       mitosis.
CC   -!- TISSUE SPECIFICITY: Highly expressed in testis and weakly in
CC       skeletal muscle, thymus and spleen. Also highly expressed in
CC       colon, ovarian, prostate, neuroblastoma, breast and cervical
CC       cancer cell lines.
CC   -!- INDUCTION: Expression is cell-cycle regulated, low in G1/S,
CC       accumulates during G2/M, and decreases rapidly after.
CC   -!- PTM: Activated by phosphorylation at Thr-288; this brings about a
CC       change in the conformation of the activation segment.
CC       Phosphorylation at Thr-288 varies during the cell cycle and is
CC       highest during M phase. Autophosphorylated at Thr-288 upon TPX2
CC       binding. Phosphorylated upon DNA damage, probably by ATM or ATR.
CC   -!- PTM: Ubiquitinated by CHFR, leading to its degradation by the
CC       proteasome (By similarity). Ubiquitinated by the anaphase-
CC       promoting complex (APC), leading to its degradation by the
CC       proteasome.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. Aurora subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- CAUTION: Although authors have considered STK6 and STK15 as two
CC       different proteins, it is clear that they are the same protein.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA23592.1; Type=Frameshift; Positions=105, 125, 129, 235, 241;
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/AURKAID730ch20q13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D84212; BAA23592.1; ALT_FRAME; mRNA.
DR   EMBL; AF008551; AAC12708.1; -; mRNA.
DR   EMBL; AF011467; AAC23448.1; -; Genomic_DNA.
DR   EMBL; AF011468; AAC63902.1; -; mRNA.
DR   EMBL; AF195947; AAF29508.1; -; Genomic_DNA.
DR   EMBL; AF195942; AAF29508.1; JOINED; Genomic_DNA.
DR   EMBL; AF195943; AAF29508.1; JOINED; Genomic_DNA.
DR   EMBL; AF195944; AAF29508.1; JOINED; Genomic_DNA.
DR   EMBL; AF195945; AAF29508.1; JOINED; Genomic_DNA.
DR   EMBL; AF195946; AAF29508.1; JOINED; Genomic_DNA.
DR   EMBL; AL121914; CAC12717.1; -; Genomic_DNA.
DR   EMBL; BC001280; AAH01280.1; -; mRNA.
DR   EMBL; BC002499; AAH02499.1; -; mRNA.
DR   EMBL; BC006423; AAH06423.1; -; mRNA.
DR   EMBL; BC027464; AAH27464.1; -; mRNA.
DR   IPI; IPI00298940; -.
DR   PIR; JC5974; JC5974.
DR   RefSeq; NP_003591.2; -.
DR   RefSeq; NP_940835.1; -.
DR   RefSeq; NP_940836.1; -.
DR   RefSeq; NP_940837.1; -.
DR   RefSeq; NP_940838.1; -.
DR   RefSeq; NP_940839.1; -.
DR   UniGene; Hs.250822; -.
DR   PDB; 1MQ4; X-ray; 1.90 A; A=125-391.
DR   PDB; 1MUO; X-ray; 2.90 A; A=107-403.
DR   PDB; 1OL5; X-ray; 2.50 A; A=122-403.
DR   PDB; 1OL6; X-ray; 3.00 A; A=122-403.
DR   PDB; 1OL7; X-ray; 2.75 A; A=122-403.
DR   PDB; 2BMC; X-ray; 2.60 A; A/B/C/D/E/F=100-403.
DR   PDB; 2C6D; X-ray; 2.20 A; A=124-398.
DR   PDB; 2C6E; X-ray; 2.10 A; A/B=123-401.
DR   PDB; 2DWB; X-ray; 2.50 A; A=122-403.
DR   PDB; 2J4Z; X-ray; 2.00 A; A/B=100-403.
DR   PDB; 2J50; X-ray; 3.00 A; A/B=126-403.
DR   PDB; 2NP8; X-ray; 2.25 A; A=125-391.
DR   PDB; 2W1C; X-ray; 3.24 A; A=122-389.
DR   PDB; 2W1D; X-ray; 2.97 A; A=122-389.
DR   PDB; 2W1E; X-ray; 2.93 A; A=122-389.
DR   PDB; 2W1F; X-ray; 2.85 A; A=122-389.
DR   PDB; 2W1G; X-ray; 2.71 A; A=122-389.
DR   PDB; 2WQE; X-ray; 2.50 A; A=127-388.
DR   PDB; 2WTV; X-ray; 2.40 A; A/B/C/D=122-403.
DR   PDB; 2WTW; X-ray; 3.30 A; A=122-403.
DR   PDB; 2X6D; X-ray; 2.80 A; A=122-403.
DR   PDB; 2X6E; X-ray; 3.35 A; A=122-403.
DR   PDB; 2X81; X-ray; 2.91 A; A=125-391.
DR   PDB; 2XNE; X-ray; 2.80 A; A=122-392.
DR   PDB; 2XNG; X-ray; 2.60 A; A=122-403.
DR   PDB; 3COH; X-ray; 2.70 A; A/B=125-391.
DR   PDB; 3E5A; X-ray; 2.30 A; A=125-391.
DR   PDB; 3EFW; X-ray; 2.29 A; A/B=1-403.
DR   PDB; 3FDN; X-ray; 1.90 A; A=123-401.
DR   PDB; 3H0Y; X-ray; 2.50 A; A=125-391.
DR   PDB; 3H0Z; X-ray; 2.92 A; A/B/C=125-391.
DR   PDB; 3H10; X-ray; 2.20 A; A/B/D=125-391.
DR   PDB; 3HA6; X-ray; 2.36 A; A=125-391.
DR   PDB; 3LAU; X-ray; 2.10 A; A=125-399.
DR   PDB; 3MYG; X-ray; 2.40 A; A=125-391.
DR   PDB; 3NRM; X-ray; 3.05 A; A=126-403.
DR   PDBsum; 1MQ4; -.
DR   PDBsum; 1MUO; -.
DR   PDBsum; 1OL5; -.
DR   PDBsum; 1OL6; -.
DR   PDBsum; 1OL7; -.
DR   PDBsum; 2BMC; -.
DR   PDBsum; 2C6D; -.
DR   PDBsum; 2C6E; -.
DR   PDBsum; 2DWB; -.
DR   PDBsum; 2J4Z; -.
DR   PDBsum; 2J50; -.
DR   PDBsum; 2NP8; -.
DR   PDBsum; 2W1C; -.
DR   PDBsum; 2W1D; -.
DR   PDBsum; 2W1E; -.
DR   PDBsum; 2W1F; -.
DR   PDBsum; 2W1G; -.
DR   PDBsum; 2WQE; -.
DR   PDBsum; 2WTV; -.
DR   PDBsum; 2WTW; -.
DR   PDBsum; 2X6D; -.
DR   PDBsum; 2X6E; -.
DR   PDBsum; 2X81; -.
DR   PDBsum; 2XNE; -.
DR   PDBsum; 2XNG; -.
DR   PDBsum; 3COH; -.
DR   PDBsum; 3E5A; -.
DR   PDBsum; 3EFW; -.
DR   PDBsum; 3FDN; -.
DR   PDBsum; 3H0Y; -.
DR   PDBsum; 3H0Z; -.
DR   PDBsum; 3H10; -.
DR   PDBsum; 3HA6; -.
DR   PDBsum; 3LAU; -.
DR   PDBsum; 3MYG; -.
DR   PDBsum; 3NRM; -.
DR   ProteinModelPortal; O14965; -.
DR   DIP; DIP-33068N; -.
DR   IntAct; O14965; 30.
DR   STRING; O14965; -.
DR   PhosphoSite; O14965; -.
DR   PRIDE; O14965; -.
DR   Ensembl; ENST00000312783; ENSP00000321591; ENSG00000087586.
DR   Ensembl; ENST00000347343; ENSP00000216911; ENSG00000087586.
DR   Ensembl; ENST00000371356; ENSP00000360407; ENSG00000087586.
DR   Ensembl; ENST00000395909; ENSP00000379245; ENSG00000087586.
DR   Ensembl; ENST00000395911; ENSP00000379247; ENSG00000087586.
DR   Ensembl; ENST00000395913; ENSP00000379249; ENSG00000087586.
DR   Ensembl; ENST00000395914; ENSP00000379250; ENSG00000087586.
DR   Ensembl; ENST00000395915; ENSP00000379251; ENSG00000087586.
DR   GeneID; 6790; -.
DR   KEGG; hsa:6790; -.
DR   CTD; 6790; -.
DR   GeneCards; GC20M054944; -.
DR   H-InvDB; HIX0015930; -.
DR   HGNC; HGNC:11393; AURKA.
DR   HPA; CAB001454; -.
DR   HPA; HPA002636; -.
DR   MIM; 603072; gene.
DR   PharmGKB; PA36201; -.
DR   HOGENOM; HBG755340; -.
DR   HOVERGEN; HBG108519; -.
DR   InParanoid; O14965; -.
DR   PhylomeDB; O14965; -.
DR   BRENDA; 2.7.11.1; 247.
DR   Pathway_Interaction_DB; aurora_a_pathway; Aurora A signaling.
DR   Pathway_Interaction_DB; aurora_b_pathway; Aurora B signaling.
DR   Pathway_Interaction_DB; aurora_kinase_pathway; Signaling by Aurora kinases.
DR   Reactome; REACT_152; Cell Cycle, Mitotic.
DR   BindingDB; O14965; -.
DR   NextBio; 26512; -.
DR   ArrayExpress; O14965; -.
DR   Bgee; O14965; -.
DR   CleanEx; HS_AURKA; -.
DR   Genevestigator; O14965; -.
DR   GermOnline; ENSG00000087586; Homo sapiens.
DR   GO; GO:0005634; C:nucleus; TAS:ProtInc.
DR   GO; GO:0005876; C:spindle microtubule; IDA:BHF-UCL.
DR   GO; GO:0031616; C:spindle pole centrosome; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0007067; P:mitosis; TAS:ProtInc.
DR   GO; GO:0048015; P:phosphoinositide-mediated signaling; NAS:UniProtKB.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; TAS:ProtInc.
DR   GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB.
DR   GO; GO:0007051; P:spindle organization; NAS:UniProtKB.
DR   InterPro; IPR020636; Ca/CaM-dep_prot_kinase-like.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR002290; Ser/Thr_prot_kinase_dom.
DR   InterPro; IPR020663; Spindle_assmbl_checkpoint_kin.
DR   PANTHER; PTHR22982; Ca/CaM-dep_prot_kinase-like; 1.
DR   PANTHER; PTHR22982:SF49; Spindle_assmbl_checkpoint_kin; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell cycle; Cell division;
KW   Complete proteome; Cytoplasm; Cytoskeleton; Kinase; Microtubule;
KW   Mitosis; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Proto-oncogene; Serine/threonine-protein kinase; Transferase;
KW   Ubl conjugation.
FT   CHAIN         1    403       Serine/threonine-protein kinase 6.
FT                                /FTId=PRO_0000086692.
FT   DOMAIN      133    383       Protein kinase.
FT   NP_BIND     210    213       ATP.
FT   REGION      280    293       Activation segment.
FT   ACT_SITE    256    256       Proton acceptor.
FT   BINDING     143    143       ATP; via amide nitrogen.
FT   BINDING     162    162       ATP.
FT   BINDING     274    274       ATP.
FT   MOD_RES      41     41       Phosphoserine.
FT   MOD_RES      51     51       Phosphoserine.
FT   MOD_RES      53     53       Phosphoserine.
FT   MOD_RES      83     83       Phosphoserine.
FT   MOD_RES     287    287       Phosphothreonine.
FT   MOD_RES     288    288       Phosphothreonine.
FT   MOD_RES     369    369       Phosphoserine.
FT   VARIANT      11     11       G -> R (in dbSNP:rs6069717).
FT                                /FTId=VAR_030840.
FT   VARIANT      31     31       F -> I (in dbSNP:rs2273535).
FT                                /FTId=VAR_030841.
FT   VARIANT      50     50       P -> L (in dbSNP:rs34572020).
FT                                /FTId=VAR_041127.
FT   VARIANT      57     57       V -> I (in dbSNP:rs1047972).
FT                                /FTId=VAR_030842.
FT   VARIANT     104    104       S -> L (in dbSNP:rs2230743).
FT                                /FTId=VAR_061745.
FT   VARIANT     155    155       S -> R (in a colorectal adenocarcinoma
FT                                sample; somatic mutation; reduces
FT                                interaction with TPX2).
FT                                /FTId=VAR_041128.
FT   VARIANT     174    174       V -> M (in a metastatic melanoma sample;
FT                                somatic mutation; constitutively enhanced
FT                                kinase activity).
FT                                /FTId=VAR_041129.
FT   VARIANT     373    373       M -> V (in dbSNP:rs33923703).
FT                                /FTId=VAR_041130.
FT   MUTAGEN     162    162       K->R: Loss of kinase activity.
FT   MUTAGEN     198    198       G->N: Reduces interaction with TPX2.
FT                                Reduces kinase activity tenfold. Promotes
FT                                interaction with the AURKB binding
FT                                partners INCENP and BIRC5 that are
FT                                normally not bound by AURKA.
FT   MUTAGEN     205    205       R->A: Reduces ubiquitination and
FT                                proteasomal degradation.
FT   MUTAGEN     274    274       D->N: Abolishes autophosphorylation.
FT   MUTAGEN     287    287       T->A: No direct effect on catalytic
FT                                activity.
FT   MUTAGEN     287    287       T->E: Enhances interaction with TPX2.
FT   HELIX       130    132
FT   STRAND      133    141
FT   STRAND      143    152
FT   TURN        153    155
FT   STRAND      158    165
FT   HELIX       166    172
FT   HELIX       175    187
FT   STRAND      196    201
FT   STRAND      203    210
FT   HELIX       218    225
FT   HELIX       230    249
FT   HELIX       259    261
FT   STRAND      262    264
FT   STRAND      270    272
FT   HELIX       275    277
FT   STRAND      279    283
FT   HELIX       298    301
FT   HELIX       309    324
FT   HELIX       334    343
FT   HELIX       354    363
FT   HELIX       368    370
FT   HELIX       374    378
FT   HELIX       381    386
SQ   SEQUENCE   403 AA;  45809 MW;  125F3594834CD157 CRC64;
     MDRSKENCIS GPVKATAPVG GPKRVLVTQQ FPCQNPLPVN SGQAQRVLCP SNSSQRVPLQ
     AQKLVSSHKP VQNQKQKQLQ ATSVPHPVSR PLNNTQKSKQ PLPSAPENNP EEELASKQKN
     EESKKRQWAL EDFEIGRPLG KGKFGNVYLA REKQSKFILA LKVLFKAQLE KAGVEHQLRR
     EVEIQSHLRH PNILRLYGYF HDATRVYLIL EYAPLGTVYR ELQKLSKFDE QRTATYITEL
     ANALSYCHSK RVIHRDIKPE NLLLGSAGEL KIADFGWSVH APSSRRTTLC GTLDYLPPEM
     IEGRMHDEKV DLWSLGVLCY EFLVGKPPFE ANTYQETYKR ISRVEFTFPD FVTEGARDLI
     SRLLKHNPSQ RPMLREVLEH PWITANSSKP SNCQNKESAS KQS
//
